CXL with MMC for Keratoconus
Study Summary
This trial is testing whether using a low concentration of MMC for a shorter duration can reduce corneal haze and scarring after CXL.
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Awards & Highlights
Trial Design
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Are there other examples where CXL has been studied in tandem with MMC?
"There are currently 45 ongoing studies that focus on CXL with MMC. Out of these, 12 have reached Phase 3 clinical trials. Although many of the investigations related to this treatment are based in Bethesda, Maryland; there are 2070 locations running similar studies across the globe."
Would someone outside of the target age range for this research be able to participate?
"Patients that meet the age requirement of 18-70 years old are eligible for this study. There are 21 other trials available for minors and 81 studies for patients older than 65."
Are we still looking for people to participate in this experiment?
"Yes, this information is available on clinicaltrials.gov. The trial was posted on 7/26/2021 and was last updated on 10/6/2021."
Could I enroll in this research project?
"64 individuals suffering from [keratoconus](https://www.withpower.com/clinical-trials/keratoconus), ranging in age from 18 to 70, are what this study require. Most importantly, potential candidates must meet the following two qualifications: They must be of either gender with confirmed progressive keratoconus or another ectatic disorder like post refractive surgery ectasia that is also progressing."
What indications are there for CXL with MMC?
"CXL with MMC is a treatment for various diseases and cancers, including cervical cancer, lg-utuc, glaucoma, and mesotheliomas."
Are there risks associated with CXL and MMC?
"CXL with MMC's safety is estimated to be a 2. This ranking comes from the fact that, while there has been some data supporting its safety, there is currently no information affirming its efficacy in Phase 2 of the trial."
What is the target number of participants for this experiment?
"That is correct. The online information hosted on clinicaltrials.gov shows that this research trial is still recruiting patients. Originally, the study was posted on 26 July 2021 and has since been edited on 6 October 2021. Currently, the study is looking for 64 individuals who are willing to participate at 1 location."